TAOX
TAO Synergies Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.89
−4.07%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -20.8%
- EBIT
- -9.7%
- EPS
- +80.0%
- Free cash flow
- -25.4%
- Operating cash flow
- -25.4%
Forward estimates
Based on analyst estimates
- Revenue
- -54.1%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -32.9%
- EBIT
- -32.8%
- Net income
- —
- EPS
- +19.8%
- Free cash flow
- -30.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026